Cited by 210Peroxisome Proliferator-Activated ReceptorsAdipose Tissue and MetabolismParaoxonase enzyme and polymorphisms

Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes

Open access
Luquet, Serge, Gaudel, Celine, Holst, Dorte, Lopez-Soriano, Joaquin, Jehl-Pietri, Chantal, Fredenrich, Alexandre, Grimaldi, Paul A.·2005·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors exerting several functions in development and metabolism. PPARalpha, activated by polyunsaturated fatty acids and fibrates, is implicated in regulation of lipid metabolism, lipoprotein synthesis and metabolism and inflammatory response in liver and other tissues. PPARgamma plays important roles in regulation of proliferation and differentiation of several cell types, including adipose cells. Its activation by thiazolidinediones results in insulin sensibilization and antidiabetic action. Until recently, the physiological functions of PPARdelta remain elusive. The utilization of specific agonists and of appropriate cellular and animal models revealed that PPARdelta has an important role in metabolic adaptation of several tissues to environmental changes. Treatment of obese animals by specific PPARdelta agonists results in normalization of metabolic parameters and reduction of adiposity. The nuclear receptor appeared to be implicated in the regulation of fatty acid burning capacities of skeletal muscle and adipose tissue by controlling the expression of genes involved in fatty acid uptake, beta-oxidation and energy uncoupling. PPARdelta is also implicated in the adaptive metabolic response of skeletal muscle to endurance exercise by controlling the number of oxidative myofibers. Given the results obtained with animal models, PPARdelta agonists may have therapeutic usefulness in metabolic syndrome by increasing fatty acid consumption in skeletal muscle and adipose tissue.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2004.11.011

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 33 · Cited by 210

Research works printed but not linked: 2

  1. B.H. Park, B. Vogelstein, K.W. Kinzler, Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2598 -2603.
  2. W.R. Oliver, J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, D.A. Winegar, M.L. Sznaidman, M.H. Lambert, H.E. Xu, D.D. Sternbach, S.A. Kliewer, B.C. Hansen, T.M. Wilson, A selective peroxisome proliferator-activated receptor y agonist promotes reverse cholesterol transport, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5306 -5311.

Authors
Luquet, S., Gaudel, C., Holst, D., Lopez-Soriano, J., Jehl-Pietri, C., Fredenrich, A., & Grimaldi, P. A.
Affiliations
Inserm (FR)
Corresponding author
Grimaldi, Paul A.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2005-05
Volume
1740
Issue
2
Pages
313-317
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2054066779
Cited by
210
References
33
Citations by year
2026: 4 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 15 · 2018: 9 · 2017: 13 · 2016: 12 · 2015: 7 · 2014: 5 · 2013: 7 · 2012: 11
FWCI
3.20
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
PPARδ, peroxisome proliferator-activated receptors, fat absorption, lipid metabolism, type 2 diabetes, PPARδ agonist, metabolic adaptation, skeletal muscle, adipose tissue, fatty acid beta-oxidation, endurance exercise, metabolic syndrome, obesity, insulin sensitivity
MeSH terms
Adipose Tissue, Animals, Carrier Proteins, Diabetes Mellitus, Type 2, Fatty Acids, Humans, Multienzyme Complexes, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism, Fatty Acid-Binding Proteins, Mitochondrial Trifunctional Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review